BioSpace News Archive

The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.

Swiss pharma giant Roche acquired Ireland’s Inflazome and its NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases for €380 million (about $451 million) in an upfront payment.

Legend’s CEO and Board Chairman, Fangliang “Frank” Zhange, was placed on “residential surveillance” by PRC law enforcement.

The overall survival benefit of Lynparza was shared this weekend, four months after the U.S. Food and Drug Administration approved it as a treatment for prostate cancer.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.

Competition for resources is growing, and the usual supply chain partners may not have available capacity in the preferred timeframe.

Genentech, a Roche company, presented data from three Phase III trials of Tecentriq (atezolizumab) in triple-negative breast cancer at the European Society for Medical Oncology Virtual Congress 2020 this weekend.

Last week, HHS Secretary Alex Azar assumed all final authority in deciding new rules regarding food, medical devices and new medications.

ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, today announced the submission of a Biologics License Application (B

Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its transaction to acquire Forbius for their TGF-beta program, including its lead investigational asset AVID200, currently in Phase 1 for oncology and fibrosis. “We are pleased to complete the transaction with Forbius and add their TGF-beta program to